Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.
IPO Year:
Exchange: NASDAQ
Website: gtglabs.com
SC 13G/A - GENETIC TECHNOLOGIES LTD (0001166272) (Subject)
SC 13G - GENETIC TECHNOLOGIES LTD (0001166272) (Subject)
CHARLOTTE, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to share the power of the geneType test in identifying risk and improving the health of populations worldwide. Since the geneType Risk Assessment Tests became available, GTG has tested a statistically significant number of people in Australia and the US. These results have revealed a compelling statistic: 79.5% of individuals tested*1 showed an elevated risk for at least one disease. GTG believes this is a significant finding driving increased surveillance and screening whi
CHARLOTTE, N.C. and MELBOURNE, Australia, June 21, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, ASX:GTG, "Company", "GTG", or "Genetic Technologies"))), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on June 27, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Simon Morriss, CEO of Genetic Technologies, who will share insight into the Company's portfolio of genomics-based tests targeting health, wellness and serious disease, including the geneType multi-risk test. The team will provide an update on four pivotal strategies: Scal
CHARLOTTE, N.C., June 18, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease, today announces the start of testing operations in the United States for its revolutionary geneType™ genetic risk assessment product series. GeneType's multi-patented, clinically validated tests will now be performed by Gene by Gene, a premier specialty genetic laboratory based in Houston, Texas, a state-of-the-art, highly accredited laboratory (CLIA, CAP, AABB and CDPH licensed). Gene by Gene's ability to process up to 25,000 tests per month greatly increases geneType's operational cap
MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease, and Stayhealthy, Inc., a leader in health and wellness technology, are excited to announce a major distribution agreement. This partnership will bring GTG's innovative Multi-Risk Test to a broader audience in the online pharmacy channel across North America, empowering individuals to take control of their health. Stayhealthy is at the forefront of integrating technology with health solutions. The company's mission is to empower, inspire, and give hope to individuals, families, and
MELBOURNE, Australia, May 29, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has released its novel Comprehensive Risk Assessment test that covers 100% of women at risk of developing breast and ovarian cancer. The innovative test, available to all women above the age of 30, assesses a woman's risk of cancer due to hereditary, including those with common gene mutations, and sporadic disease. Launched at the inaugural "Know Your Risk" event in California, USA, the event provided invaluable insights of the role of genomic
PASADENA, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GeneType")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce that the Know Your Risk event held yesterday at The Langham Pasadena has set a new standard for women's health initiatives, highlighting the transformative potential of genetic testing and risk assessment. Organized by GeneType and Humanise Health, in partnership with Thermo Fisher Scientific and Creators Entertainment Group, this landmark event was not merely a gathering, but a movement aimed at empowering women with the knowledge to take control of their hea
MELBOURNE, Australia, May 06, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the execution of a strategic joint sales & marketing agreement with US based Wellworks for You Inc. (Wellworks). As part of the agreement, Wellworks will incorporate the geneType portfolio of tests into its fully flexible, scalable employee wellness solutions for organizations and businesses across the U.S, providing direct access to more than two million personnel. Executing GTG's inaugural Business to Business (B2B) collaboration with U.S. based Wellworks fa
MELBOURNE, Australia, April 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX:GTG, NASDAQ:GENE, "Company", "GTG", or "Genetic Technologies")), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announces the closing of its previously announced registered offering for the purchase and sale of 1,000,000 American Depositary Shares ("ADSs") (or ADS equivalents in lieu thereof), each representing thirty (30) ordinary shares of the Company, at an offering price of US$2.00 per ADS. In addition, in a concurrent private placement, the Company has issued unregistered warrants ("Warrants") to purchase up to 1,000,000 ADSs. The W
MELBOURNE, Australia, April 19, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX:GTG, NASDAQ:GENE, ", Company", , ", GTG", , or ", Genetic Technologies", )), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced that it has entered into a definitive agreement for the purchase and sale in a registered direct offering of 1,000,000 American Depositary Shares ("ADSs") (or ADS equivalents in lieu thereof), each representing thirty (30) ordinary shares of the Company, at a purchase price of $2.00 per ADS. In addition, in a concurrent private placement, the Company will issue unregistered warrants ("Warrants") to purchase up
MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GENE")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to share the company's latest milestones along with our clinical adoption of the Company's groundbreaking geneType Risk Assessment Tests routinely across 12 states in the United States and nationally in Australia. The geneType team has achieved clinical proof of concept in key markets including general practice, oncology, and gynecology with repeat sales in each of these markets. Increasingly clinicians are realising the importance of genetic screening for dis
GAINERS: GreenGro Technologies (OTC:GRNH) shares closed up 900.00% at $1e-05 CordovaCann (OTC:LVRLF) shares closed up 50.89% at $0.07 1933 Industries (OTC:TGIFF) shares closed up 47.06% at $0.01 Kaya Holdings (OTC:KAYS) shares closed up 29.70% at $0.04 Target Group (OTC:CBDY) shares closed up 24.28% at $0.00 Global Compliance (OTC:FUAPF) shares closed up 23.20% at $0.01 MJ Holdings (OTC:MJNE) shares closed up 22.41% at $0.00 CV Sciences (OTC:CVSI) shares closed up 19.77% at $0.06 Pharmadrug (OTC:LMLLF) shares closed up 11.11% at $0.01 4Front Ventures (OTC:FFNTF) shares closed up 10.95% at $0.07 Eastside Distilling (NASDAQ:EAST) shares closed up 7.29% at $0.97 Genetic Technologies (NASDAQ:GE
GAINERS: Plant Based Investment (OTC:CWWBF) shares closed up 9900.00% at $0.0001 Elixinol Wellness (OTC:ELLXF) shares closed up 26.00% at $0.00 Maple Leaf Green World (OTC:MGWFF) shares closed up 20.87% at $0.03 Global Hemp Group (OTC:GBHPF) shares closed up 10.82% at $0.04 Charlottes Web Holdings (OTC:CWBHF) shares closed up 10.58% at $0.20 1933 Industries (OTC:TGIFF) shares closed up 8.11% at $0.01 Trulieve Cannabis (OTC:TCNNF) shares closed up 6.16% at $10.51 22nd Century Group (NASDAQ:XXII) shares closed up 5.63% at $0.79 Zoned Props (OTC:ZDPY) shares closed up 5.26% at $0.65 RIV Capital (OTC:CNPOF) shares closed up 5.21% at $0.10 Cresco Labs (OTC:CRLBF) shares closed up 5.00% at $1.78
GAINERS: Global Hemp Group (OTC:GBHPF) shares closed up 29.87% at $0.03 Target Group (OTC:CBDY) shares closed up 15.79% at $0.00 Body and Mind (OTC:BMMJ) shares closed up 14.14% at $0.05 Kaya Holdings (OTC:KAYS) shares closed up 11.63% at $0.05 Rocky Mountain High (OTC:RMHB) shares closed up 11.33% at $0.02 Blueberries Medical (OTC:BBRRF) shares closed up 11.11% at $0.01 CLS Holdings USA (OTC:CLSH) shares closed up 9.45% at $0.05 MJ Holdings (OTC:MJNE) shares closed up 8.89% at $0.00 CV Sciences (OTC:CVSI) shares closed up 4.32% at $0.06 Genetic Technologies (NASDAQ:GENE) shares closed up 4.07% at $1.48 Mexco Energy (AMEX:MXC) shares closed up 3.47% at $11.34 AusCann Group Holdings (OTC:ACN
Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to share the power of the geneType test in identifying risk and improving the health of populations worldwide. Since the geneType Risk Assessment Tests became available, GTG has tested a statistically significant number of people in Australia and the US. These results have revealed a compelling statistic: 79.5% of individuals tested*0F1 showed an elevated risk for at least one disease. GTG believes this is a significant finding driving increased surveillance and screening which will ultimately lead to early detection, early int
GAINERS: MJ Holdings (OTC:MJNE) shares closed up 50.94% at $0.01 Global Hemp Group (OTC:GBHPF) shares closed up 33.33% at $0.04 CNBX Pharmaceuticals (OTC:CNBX) shares closed up 17.69% at $0.01 1933 Industries (OTC:TGIFF) shares closed up 13.53% at $0.01 SOL Glb Inv (OTC:SOLCF) shares closed up 9.78% at $0.04 Greenlane Hldgs (NASDAQ:GNLN) shares closed up 7.05% at $0.58 Psychemedics (NASDAQ:PMD) shares closed up 6.33% at $2.43 Urban-gro (NASDAQ:UGRO) shares closed up 6.00% at $1.49 Eastside Distilling (NASDAQ:EAST) shares closed up 3.60% at $1.00 Scotts Miracle Gro (NYSE:SMG) shares closed up 3.40% at $67.53 Nextleaf Solutions (OTC:OILFF) shares closed up 3.01% at $0.09 LOSERS: MPX Interna
GAINERS: The Flowr (OTC:FLWPF) shares closed up 9900.00% at $0.0001 AusCann Group Holdings (OTC:ACNNF) shares closed up 150.00% at $0.01 CordovaCann (OTC:LVRLF) shares closed up 40.64% at $0.09 Elixinol Wellness (OTC:ELLXF) shares closed up 38.40% at $0.00 Rocky Mountain High (OTC:RMHB) shares closed up 23.81% at $0.01 CV Sciences (OTC:CVSI) shares closed up 21.25% at $0.10 Leafbuyer Techs (OTC:LBUY) shares closed up 13.68% at $0.03 Auxly Cannabis Group (OTC:CBWTF) shares closed up 10.54% at $0.02 Psychemedics (NASDAQ:PMD) shares closed up 8.62% at $2.37 Cannabix Technologies (OTC:BLOZF) shares closed up 8.24% at $0.50 Blueberries Medical (OTC:BBRRF) shares closed up 7.99% at $0.01 EnWave (
Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease, and Stayhealthy, Inc., a leader in health and wellness technology, are excited to announce a major distribution agreement. This partnership will bring GTG's innovative Multi-Risk Test to a broader audience in the online pharmacy channel across North America, empowering individuals to take control of their health. Stayhealthy is at the forefront of integrating technology with health solutions. The company's mission is to empower, inspire, and give hope to individuals, families, and communities through enhanced technology and a global wellne
Gainers Cue Health (NASDAQ:HLTH) stock moved upwards by 44.2% to $0.08 during Thursday's pre-market session. The market value of their outstanding shares is at $12.5 million. OneMedNet (NASDAQ:ONMD) stock increased by 42.05% to $2.77. The company's market cap stands at $66.0 million. Kintara Therapeutics (NASDAQ:KTRA) shares moved upwards by 33.23% to $0.36. The company's market cap stands at $20.0 million. Nexalin Technology (NASDAQ:NXL) stock rose 15.6% to $0.78. The market value of their outstanding shares is at $5.8 million. Gain Therapeutics (NASDAQ:GANX) shares moved upwards by 13.44% to $2.7. The market value of their outstanding shares is at $48.7 million. Jaguar Health (NASDAQ
GAINERS: Global Hemp Group (OTC:GBHPF) shares closed up 218.18% at $0.07 1933 Industries (OTC:TGIFF) shares closed up 43.96% at $0.01 Rocky Mountain High (OTC:RMHB) shares closed up 14.41% at $0.01 Target Group (OTC:CBDY) shares closed up 14.29% at $0.00 Urban-gro (NASDAQ:UGRO) shares closed up 9.98% at $1.56 RIV Capital (OTC:CNPOF) shares closed up 7.29% at $0.09 Leafbuyer Techs (OTC:LBUY) shares closed up 3.54% at $0.02 CV Sciences (OTC:CVSI) shares closed up 3.45% at $0.06 LOSERS: The Flowr (OTC:FLWPF) shares closed down 50.00% at $0.0001 Heritage Cannabis Holding (OTC:HERTF) shares closed down 25.00% at $0.00 Affinor Growers (OTC:RSSFF) shares closed down 20.00% at $0.08 Genetic Techn
MELBOURNE, Australia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, "Company", "GTG"))), is pleased to announce the launch of a wide-reaching customer – targeted digital advertising campaign in the United States. This comprehensive program will drive Consumer Initiated Testing (CIT) for the company's geneType Risk Assessment Tests. The campaign will commence end of March 2024 and will scale up throughout the remainder of the year. The U.S. wellness testing market is projected to reach $4.9 billion by 2032 from $878.9 million in 2022 with an annual growth rate of 18.86%1. GTG's strategy ensures that the company's geneType Risk Assessment test portfolio will be
MELBOURNE, Australia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE), is at the forefront in personalised predictive genomics, reshaping the healthcare landscape with its inventive strategy for early disease detection and personalized wellness is pleased to share Business update for the quarter ending 31 December 2023 (Q2 FY24). GENE's pioneering initiatives in genomics-based tests place it at the forefront of precision medicine. Leading the world in risk prediction in oncology, cardiovascular, and metabolic diseases, Genetic Technologies continues to develop cutting edge risk assessment products to capitalize on the burgeoning clinical and consumer personali
MELBOURNE, Australia, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG", "GENE")), a global leader in guideline driven genomics-based tests in health, wellness and serious disease, is pleased to report excellent commercial progress in the USA strategic operations with the following updates: Strategic Highlights: Active engagement with 11 US payer groups with an initial target list of 30 with coverage in tens of millions of livesEngagement with 19 US Concierge Medicine Practices with large volume pricing discussionsCommercial evaluations underway at 10 US medical/family practicesRe-engagement with 1,600 previous geneType US custo
MELBOURNE, Australia, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GENE")), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to report annual results for the year ended June 30, 2022. It has been an exciting 12 months focused on our commercialisation journey. We now have the most comprehensive portfolio of genetic based tests available for individuals and animals. In addition to our patented geneType polygenic based risk tests, our portfolio includes pharmacogenomics, Non-Invasive Prenatal Testing (NIPT), carrier screen testing, oncogenetic diseases, and pet care. This year w
MELBOURNE, Australia, April 12, 2021 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company")), announces the appointment of Michael Tonroe to the role of Chief Financial Officer, commencing on 28 June 2021. Michael has over 25 years' experience in overseeing the finance function at both management and board-level positions for private and listed companies in Australia, UK, US and Canada. He also has extensive experience in the biotech space across both the financial and company secretary roles having most recently managed both functions for dual-listed Opthea Limited. Commenting on the appointment, Chairman, Peter Rubinstein said
MELBOURNE, Australia, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, the ‘Company’), announced today that they have entered into a three-year partnership agreement with mental health company, Taliaz, for the distribution rights of their PREDICTIX products in Australia, New Zealand and the USA (“Agreement”). Key Highlights Expands GTG’s product offering and establishes the mental health vertical through distribution partnership agreement harnessing PREDICTIX, Taliaz’s CE-registered, genomic-based, AI driven antidepressant selection technology that can improve today’s antidepressant prescribing accuracy by 47%4Potential
ORLANDO, FL / ACCESSWIRE / April 12, 2024 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, April 13, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Genetic Technologies: https://www.redchip.com/assets/access/gene_accessBioVie: https://www.redchip.com/assets/access/bivi_accessIn an exclusive interview, Simon Morriss, CEO of Genetic Technologies, appears on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV to provide a corp
ORLANDO, FL / ACCESSWIRE / December 29, 2023 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, December 30, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Genetic Technologies: https://www.redchip.com/assets/access/gene_accessBioVie: https://www.redchip.com/assets/access/bivi_accessIn an exclusive interview, Simon Morriss, CEO of Genetic Technologies, appears on the RedChip Small Stocks Big Money® Show on Bloomberg TV to provide a
ORLANDO, FL / ACCESSWIRE / October 6, 2023 / RedChip Companies will air interviews with Knightscope, Inc. (NASDAQ:KSCP), Soligenix, Inc. (NASDAQ:SNGX), and Genetic Technologies Limited (ASX:GTG)(NASDAQ:GENE) on The RedChip Small Stocks Big Money Show®, a sponsored program on Bloomberg TV, this Saturday, October 7, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Knightscope: https://www.redchip.com/assets/access/knightscope_access.htmlSoligenix: https://www.redchip.com/assets/access/sngx_accessGenetic Technologies: https://www.redchip.com/assets/access/gene_accessWilliam Santana Li, CEO and Chair
ORLANDO, FL / ACCESSWIRE / September 15, 2023 / RedChip Companies will air interviews with Aridis Pharmaceuticals, Inc. (OTC:ARDS), Genetic Technologies Limited ((ASX:GTG, NASDAQ:GENE), and American Resources Corporation (NASDAQ:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 16, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Aridis Pharmaceuticals: https://www.redchip.com/assets/access/ards_accessGenetic Technologies: https://www.redchip.com/assets/access/gene_accessAmerican Resources: https://www.redchip.com/assets/access/arec_accessAbout The
MELBOURNE, Australia, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to advise that RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and 60 Degrees Pharmaceuticals (60P) (NASDAQ:SXTP) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interviews in their entirety at: • Genetic Technologies (NASDAQ:GENE): https://www.redchip.com/
ORLANDO, FL / ACCESSWIRE / September 1, 2023 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Genetic Technologies (NASDAQ:GENE): https://www.redchip.com/stocks/GENE60 Degrees Pharmaceuticals (NASDAQ:SXTP): https://www.redchip.com/stocks/SXTPAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations a
ORLANDO, FL / ACCESSWIRE / October 13, 2022 / RedChip Companies will air a new interview with Genetic Technologies Limited (ASX:GTG)(NASDAQ:GENE) ("Company", "GTG"), a global leader in genomics-based tests in health, wellness, and serious disease, on The RedChip Money Report® on Bloomberg TV, this Saturday, October 15, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Genetic Technologies Limited's CEO Simon Morriss discusses the Company's expanded portfolio of tests, global relationships and partnerships, revenue growth channels, reported five consecutive quarters of gr
MELBOURNE, Australia, July 14, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GENE")), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce that it has completed the acquisition of the direct-to-consumer eCommerce business and distribution rights associated with AffinityDNA as announced on May 16, 20221. Acquisition Highlights: Strategic acquisition strengthens the direct-to-consumer channel for GENE, building on the incremental EasyDNA expansion opportunities recently announced (ASX July 5, 20222).Provides additional platform for growth in the multibillion-dollar consumer geno
FORT LAUDERDALE, Fla., Sept. 9, 2021 /PRNewswire/ -- September 9, 2021–BelHealth Investment Partners, LLC ("BelHealth") is pleased to announce that it has completed the sale of assets of the international division of General Genetics Corporation (GGC), a provider of relationship and clinical genetic testing services, to Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE) is a diversified molecular diagnostics company ("GTG"). The transaction was structured in a combination of cash and stock of GTG. "We are pleased to see this transaction come to fruition," said Inder Tallur.Founded in 2013, GGC, managed its non-US based direct-to-consumer (DTC) genetic testing business consisting of trad
MELBOURNE, Australia, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GENE")), a global leader in Genomics based tests in health, wellness and serious disease, is pleased to announce the completion of its acquisition of EasyDNA (‘the acquisition') for US$4 million in cash and stock on August 13, 2021. Overview BelHealth becomes a shareholder of Genetic Technologies with 2.3% holding following completion of EasyDNA acquisitionProvides for global expansion into genomics based "Health and Wellness" in 40 countries and a significant platform for the sale and expansion of existing and future productsEasyDNA currently sells paternity, onc
6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)
6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)
6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)
6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)
6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)
EFFECT - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)
6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)
6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)
6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)
6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)